Based on a series of six lectures discussing some of the special considerations which arise when a science based industry has the government as a major customer in its home market, with particular reference to the relationship between the pharmaceutical industry and the National Health Service. The book challenges conventional attitudes to costing, pricing and marketing which in the past have been applied to science-based industry. The first paper discusses the influence of patents on the pattern of progress. The second paper challenges conventional economic concepts, and discusses new criteria on which the economic performance of science-based industries could be judged. The third paper describes the role of marketing in scientific progress, emphasizing that scientific advances are not adopted in to practice until they have been successfully sold, and the fourth is devoted specifically to a description of the international pattern of pharmaceutical research, discussing the way in which it is organized and financed. The fifth paper describes government relations with a research-based industry, drawing attention to difficulties which have arisen with electronics, aircraft, etc. This book will be welcomed by all those with an interest in science-based industry, its economics, and its relationship with government; by civil servants, administrators and members of committees; and by all students of this important subject.